Logo Image
Viewing
|Articles|January 12, 2021

Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Related Content

Latest CME

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis
Video

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

View more
The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes
Video

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

View more
Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida
Video

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

View more
(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights
Video

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

View more